CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
Provided By PR Newswire
Last update: May 29, 2024
Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024
Cash and cash equivalents balance as of March 31, 2024, was $23.2 million
Read more at prnewswire.comNASDAQ:CLGN (2/21/2025, 8:09:58 PM)
3.47
-0.01 (-0.22%)
Find more stocks in the Stock Screener
